Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line

Cancer Research

Volumn 59, Issue 23, 1999, Pages 5956-5963

  Månsson, Emma ^a   Spasokoukotskaja, Tatiana ^b   Sällström, Jan ^c   Eriksson, Staffan ^d   Albertioni, Freidoun ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; DEOXYGUANOSINE KINASE; FLUDARABINE;

ARTICLE; CELL LINE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MUTATION; PRIORITY JOURNAL; PROMYELOCYTE; PROTEIN EXPRESSION; QUANTITATIVE ASSAY;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BIOTRANSFORMATION; CELL SURVIVAL; CLADRIBINE; DNA, NEOPLASM; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HL-60 CELLS; HUMANS; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; VIDARABINE;

EID: 0033406797     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Bryson, H. M., and Sorkin, E. M. Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies. Drugs, 46: 872-894, 1993.
2. Beutler, E., Sipe, J., Romine, J., McMillan, R., Zyroff, J., and Koziol, J. Treatment of multiple sclerosis and other autoimmune diseases with cladribine. Semin. Hematol., 33: 45-52, 1996.
3. Grever, M. R., Kopecky, K. J., Coltman, C. A., Files, J. C., Greenberg, B. R., Hutton, J. J., Talley, R., Von Hoff, D. D., and Balcerzak, S. P. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv. Res. Fr. Hematol., 30: 457-459, 1988.
4. Leiby, J. M., Snider, K. M., Kraut, E. H., Metz, E. N., Malspeis, L., and Grever, M. R. Phase II trial of 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity. Cancer Res., 47: 2719-2722, 1987.
5. Plunkett, W., and Saunders, P. P. Metabolism and action of purine nucleoside analogs. Pharmacol. Ther., 49: 239-268, 1991.
6. Keating, M. J. Leukemia. A model for drug development. Clin. Cancer Res., 3: 2598-2604, 1997.
7. Juliusson, G., Elmhorn-Rosenborg, A., and Liliemark, J. Response to 2-chlorode-oxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N. Engl. J. Med., 327: 1056-1061, 1992.
8. Kawasaki, H., Carrera, C. J., Piro, L. D., Saven, A., Kipps, T. J., and Carson, D. A. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood, 81: 597-601, 1993.
9. Wang, L., Karlsson, A., Amer, E. S., and Eriksson, S. Substrate specificity of mitochondrial 2′-deoxyguanosine kinase. Efficient phosphorylation of 2-chlorode-oxyadenosine. J. Biol. Chem., 268: 22847-22852, 1993.
10. Zhu, C., Johansson, M., Permert, J., and Karlsson, A. Enhanced cytotoxicity of nucleoside analogs by overexpression of mitochondrial deoxyguanosine kinase in cancer cell lines. J. Biol. Chem., 12: 14707-14711, 1998.
11. Griffig, J., Koob, R., and Blakley, R. L. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res., 49: 6923-6928, 1989.
12. Fidias, P., Chabner, B. A., and Grossbard, M. L. Purine analogs for the treatment of low-grade lymphoproliferative disorders. Oncologist, 1: 125-139, 1996.
13. Benjamin, R. C., and Gill, D. M. Poly(ADP-ribose) synthesis in vitro programmed by damaged DNA. A comparison of DNA molecules containing different types of strand breaks. J. Biol. Chem., 255: 10502-10508, 1980.
14. Carson, D. A., Carrera, C. J., Wasson, D. B., and Yamanaka, H. Programmed cell death and adenine deoxynucleotide metabolism in human lymphocytes. Adv. Enzyme Regul., 27: 395-404, 1988.
15. Brockman, R. W., Schabel, F. M., Jr., and Montgomery, J. A. Biologic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-D-arabinofuranosyladenine. Biochem. Pharmacol., 26: 2193-2196, 1977.
16. Plunkett, W., Chubb, S., Alexander, L., and Montgomery, J. A. Comparison of the toxicity and metabolism of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res., 40: 2349-2355, 1980.
17. Parker, W. B., Shaddix, S. C., Chang, C. H., White, E. L., Rose, L. M., Brockman, R. W., Shortnacy, A. T., Montgomery, J. A., Secrist, J. A., III, and Bennett, L. L., Jr. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res., 51: 2386-2394, 1991.
18. Huang, P., and Plunkett, W. Action of 9-β-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism. Mol. Pharmacol., 39: 449-455, 1991.
19. Leoni, L. M., Chao, Q., Cottam, H. B., Genini, D., Rosenbach, M., Carrera, C. J., Budihardjo, I., Wang, X., and Carson, D. A. Induction of an apoptotic program in cell-free extracts by 2-chloro-2′-deoxyadenosine 5′-triphosphate and cytochrome c. Proc. Natl. Acad. Sci. USA, 95: 9567-9571, 1998.
20. Leoni, L. M., Genini, D., Plunkett, W., Carrera, C. J., and Carson, D. A. Nucleotide requirement for the in vitro activation of APAF-1-mediated caspase pathway. J. Biol. Chem., in press.
21. Orr, R. M., Talbot, D. C., Aherne, W. G., Fisher, T. C., Serafinowski, P., and Harrap, K. R. 2′-Deoxycytidine kinase deficiency is a major determinant of 2-chloro-2′-deoxyadenosine resistance in lymphoid cell lines. Clin. Cancer Res., 1: 391-398, 1995.
22. Albertioni, F., Reichelova, B., Pettersson, B., Juliusson, G., and Liliemark, J. Mechanisms of cladribine resistance in a human lymphoid, CCRF-CEM cell line. Proc. Am. Assoc. Cancer Res., 37: 316, 1996.
23. Arner, E. S., Spasokoukotskaja, T., Juliusson, G., Liliemark, J., and Eriksson, S. Phosphorylation of 2-chlorodeoxyadenosine (CdA) in extracts of peripheral blood mononuclear cells of leukaemic patients. Br. J. Haematol., 87: 715-718, 1994.
24. Schirmer, M., Stegmann, A. P., Geisen, F., and Konwalinka, G. Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5′-nucleotidase activity. Exp. Hematol., 26: 1223-1228, 1998.
25. Månsson, E., Spasokoukotskaja, T., Jönsson, S., Eriksson, S., and Albertioni, F. Characteristics of 2-chloro-2′-deoxyadenosine (CdA) and fludarabine (Fara-A) acquired resistance in a human promyelocytic cell line. Proc. Am. Assoc. Cancer Res., 40: 677, 1999.
26. Gallagher, R., Collins, S., Trujillo, J., McCredie, K., Ahearn, M., Tsai, S., Metzgar, R., Aulakh, G., Ting, R., Ruscetti, F., and Gallo, R. Characterization of the continuous, differentiating myeloid cell line (HL60) from a patient with acute promyelocytic leukemia. Blood, 54: 713-733, 1979.
27. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65: 55-63, 1983.
28. Reichelova, V., Albertioni, F., and Liliemark, J. Determination of 2-chloro-2′-deoxyadenosine nucleotides in leukemic cells by ion-pair high-performance liquid chromatography. J. Chromatogr. B Biomed. Appl., 682: 115-123, 1996.
29. Sherman, P. A., and Fyfe, J. A. Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleolides as template primers. Anal. Biochem., 180: 222-226, 1989.
30. van Moorsei, C. J., Pinedo, H. M., Veerman, G., Guechev, A., Smid, K., Loves, W. J., Vermorken, J. B., Postmus, P. E., and Peters, G. J. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines. Biochem. Pharmacol., 57: 407-415, 1999.
31. Plunkett, W., Chubb, S., and Barlogie, B. Simultaneous determination of 1-β-D-arabinofuranosylcytosine 5′-triphosphate and 3-deazauridine 5′-triphosphate in human leukemia cells by high-performance liquid chromatography. J. Chromatogr., 221: 425-430, 1980.
32. Spasokoukotskaja, T., Amer, E. S., Brosjo, O., Gunven, P., Juliusson, G., Liliemark, J., and Eriksson, S. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. Eur. J. Cancer, 2: 202-208, 1995.
33. Hatzis, P., Al-Madhoon, A. S., Jüllig, M., Petrakis, T. G., Eriksson, S., and Talianidis, I. The intracellular localization of deoxycytidine kinase. J. Biol. Chem., 273: 30239-30243, 1998.
34. Wang, L., Hellman, U., and Eriksson, S. Cloning and expression of human mitochondrial deoxyguanosine kinase cDNA. FEBS Lett., 390: 39-43, 1996.
35. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. Protein measurement with the folin phenol reagent. J. Biol. Chem., 193: 265-275, 1951.
36. Gibson, U. E., Heid, C. A., and Williams, P. M. A novel method for real time quantitative RT-PCR. Genome Res., 6: 995-1001, 1996.
37. Hershfield, M. S., Fetter, J. E., Small, W. C., Bagnara, A. S., Williams, S. R., Ullman, B., Martin, D. W., Jr., Wasson, D. B., and Carson, D. A. Effects of mutational loss of adenosine kinase and deoxycytidine kinase on deoxyATP accumulation and deoxyadenosine toxicity in cultured CEM human T-lymphoblastoid cells. J. Biol. Chem., 257: 6380-6386, 1982.
38. Meuth, M. Deoxycytidine kinase-deficient mutants of Chinese hamster ovary cells are hypersensitive to DNA alkylating agents. Mutat. Res., 110: 383-391, 1983.
39. Owens, J. K., Shewach, D. S., Ullman, B., and Mitchell, B. S. Resistance to 1-β-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res., 52: 2389-2393, 1992.
40. Hapke, D. M., Stegmann, A. P., and Mitchell, B. S. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res., 56: 2343-2347, 1996.
41. Sjöberg, A. H., Wang, L., and Eriksson, S. Substrate specificity of human recombinant mitochondrial deoxyguanosine kinase with cytostatic and antiviral purine and pyrimidine analogs. Mol. Pharmacol., 53: 270-273, 1998.
42. Leegwater, P. A., De Abreu, R. A., and Albertioni, F. Analysis of DNA methylation of the 5′ region of the deoxycytidine kinase gene in CCRF-CEM-sensitive and cladribine (CdA)- and 2-chloro-2-arabino-fluoro-2′-deoxyadenosine (CAFdA)-resistant cells. Cancer Lett., 130: 169-173, 1998.
43. Xie, K. C., and Plunkett, W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine. Cancer Res., 56: 3030-3037, 1996.
44. Meuth, M., and Green, H. Alterations leading to increased ribonucleotide reductase in cells selected for resistance to deoxynucleosides. Cell, 3: 367-374, 1974.
45. Martin, D. W., Jr., and Gelfand, E. W. Biochemistry of diseases of immunodevelopment. Annu. Rev. Biochem., 50, 845-877, 1981.
46. Weinberg, G., Ullman, B., and Martin, D. W., Jr. Mutator phenotypes in mammalian cell mutants with distinct biochemical defects and abnormal deoxyribonucleoside triphosphate pools. Proc. Natl. Acad. Sci. USA, 78: 2447-2451, 1981.
47. Caras, I. W., and Martin, D. W., Jr. Molecular cloning of the cDNA for a mutant mouse ribonucleotide reductase M1 that produces a dominant mutator phenotype in mammalian cells. Mol. Cell. Biol., 8: 2698-2704, 1988.
48. Flasshove, M., Strumberg, D., Ayscue, L., Mitchell, B. S., Tirier, C., Heit, W., Seeber, S., and Schutte, J. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to 1-β-D-arabinofuranosylcytosine. Leukemia (Baltimore), 8: 780-785, 1994.